Secondary Cytoreductive Surgery May Benefit Platinum-Sensitive Ovarian Cancer Patients
Second surgery should still be offered
Researchers are still working on the overall survival data comparing the two different treatment groups. The authors summarized their current findings and concluded that second surgery should still be offered as a good treatment option in patients, even if they have a positive AGO-score indicating a better prognosis. Until they can evaluate the overall survival data, they feel there is not enough evidence to support chemotherapy as an adequate alternative.
